TrialScope’s Trial Results Summaries Portal Expands User Interface to 45 Languages

Share Article

TrialScope’s Trial Results Summaries portal will more than triple its available user interface translations, rolling out an additional 35 languages over the next three months.

TrialScope’s Trial Results Summaries portal (, the world’s largest digital library of clinical trial plain-language summaries (PLS), is expanding in functionality to help trial sponsors engage with a growing global audience. TrialScope has kicked off an ambitious project that will more than triple the portal’s available user interface translations, rolling out an additional 35 languages over the next three months. AstraZeneca, the founding member of and which has shared hundreds of clinical study results on the portal, has championed the expansion, supporting it as part of its longstanding commitment to clinical trial transparency and accessibility.

This enhancement comes on the heels of continued growth this year for the portal. has added four new study sponsors, alongside AstraZeneca, that have made a commitment to trial transparency by sharing clinical study summary results via the platform.

As clinical trial transparency trends upward across the pharmaceutical industry, an increasing number of sponsors are implementing PLS programs. Plain-language summaries must not include any promotional content, which is why many sponsors now opt to post their clinical trial results on a non-branded portal such as Trial Results Summaries. The portal already hosts clinical trial results from more than 800 industry studies from 2015 to present. Sponsors who post study results on the portal are already able and encouraged to do so in as many languages as relevant to study participants. A 2020 patient insight report by the James Lind Institute reveals that, in non-English-speaking countries, 90 percent of participants want trial feedback in their own language.

Eighty-five percent of respondents say it’s important to receive a summary of clinical research study results, according to the 2019 Perceptions & Insights Study from the Center for Information and Study on Clinical Research Participation (CISCRP). However, an alarming 61 percent of clinical trial participants did not receive any post-study reports or updates.

Posting trial results online is convenient for sponsors, reduces the burden on sites and enables easy access for the public. Through digital distribution, sponsors can avoid the cost and effort of printing and distributing PLS at trial sites, particularly when versions in multiple languages are needed. At, visitors can subscribe by sharing only an email address, democratizing access while sharing very limited personal information. This solution expedites accessibility for trial participants, who often wait months or years for trial results to be made available.

“Throughout the industry, an increasing number of sponsors are realizing the value of clinical trial transparency beyond regulatory compliance,” said Francine Lane, TrialScope Vice President for Global Transparency. “Sharing study results in plain language shows participating patients that their contribution to the study was valued and respected. And when sponsors share translations of complex medical information, participants and the public can easily comprehend results in their language of choice.”

For more information on the Trial Results Summaries portal, contact TrialScope at or +1 877-658-8310.

About TrialScope
TrialScope gives your clinical trial data superpowers™. The TrialScope Transparency Cloud™ makes centralizing, structuring and activating clinical trial information simple, for use across the organization and at every stage of the study. Our integrated platform is used by 16 of the top 20 clinical trial sponsors in the world, who rely on TrialScope to ensure disclosure compliance, maximize trial transparency, improve patient engagement and accelerate study recruitment. To learn more, visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Darcy Grabenstein
+1 929-278-5784
Email >
Visit website